Related Experiment Video
Updated: Mar 28, 2026
Imaging of Estrogen Receptor-α in Rat Pial Arterioles using a Digital Immunofluorescent Microscope
Published on: November 29, 2011
Analysis of informativeness of immunohistochemical and flow cytometric methods for estrogen receptor α assessment
T A Bogush1, E A Dudko2, M V Rodionova2
1Blokhin Cancer Research Center, Russian Academy of Medical Science, Kashirskoe sh. 24, Moscow, 115478, Russia. bogush@orc.ru.
Insights
Immunohistochemistry (IHC) and flow cytometry (FCM) show similar estrogen receptor alpha (ERα) expression frequencies in breast cancer. FCM detects low ERα levels more often than IHC, offering a more sensitive assessment for ERα status.
Area of Science:
- Oncology
- Biopathology
- Molecular Diagnostics
Background:
- Estrogen receptor alpha (ERα) is a critical biomarker in breast cancer treatment decisions.
- Accurate assessment of ERα expression is vital for effective endocrine therapy selection.
- Immunohistochemistry (IHC) and flow cytometry (FCM) are common methods for ERα evaluation, but discrepancies exist.
Purpose of the Study:
- To compare the informative capacity of IHC and FCM for assessing ERα expression in breast cancer.
- To identify and quantify differences in ERα detection between IHC and FCM.
- To propose methods for minimizing errors in routine clinical ERα status determination.
Main Methods:
- Comparative analysis of ERα expression using IHC and FCM on breast cancer tissue samples.
- Quantitative assessment of ERα-positive, ERα-negative, and low-level ERα expression by both techniques.
- Evaluation of discordant results between IHC and FCM.
Main Results:
- Both IHC and FCM demonstrated similar overall ERα expression frequencies (27% negative, 73% positive).
- FCM detected low ERα levels in 48% of positive cases, significantly higher than IHC (20%).
- FCM identified positive ERα expression in 33% of cases negative by IHC, and zero expression in 12.5% of IHC-positive cases.
Conclusions:
- FCM offers a more sensitive detection of low ERα expression compared to IHC.
- Discrepancies between IHC and FCM highlight potential for improved accuracy in ERα assessment.
- Refined methodologies are needed to minimize errors and enhance the reliability of ERα status determination in clinical practice.
Abstract:
Informative capacity analysis of immunohistochemistry (IHC) and flow cytometry (FCM) in the assessment of estrogen receptor α (ERα) expression in breast cancer tissue was performed. Similar frequencies of expression were shown by both methods: 27% of ERα-negative and 73% ERα-positive cases. However, IHC evaluation detected low levels in only 20% of ERα-positive cases, whereas low levels of ERα detected by FCM were 2 times more often (48%). Moreover, FCM revealed positive expression (23-60%) in 33% of IHC ERα-negative cases. Among IHC ER-positive cases, zero ERα expression was detected by FCM in 12.5%. The approaches to minimize errors in routine clinical determination of the estrogen receptor status were proposed.
